Vita Biotech Research has entered into a significant partnership with Cannabis Bioscience International Holdings, to fund the clinical data collection efforts of CBIH?s rigorous data clinical studies, underscoring Vita Biotech's commitment to supporting cutting-edge research and ensuring the highest standards of clinical data integrity. Through this strategic alliance, Vita Biotech will act as a financial subsidiary and catalyst for CBIH's data collection trials, a vital phase in evaluating the efficacy and safety of its formulations before they reach the market. This accelerated funding is expected to speed up CBIH's progress toward its scientific and commercial goals.

Furthermore, this collaboration allows CBIH to chart a course of its reconstruction process as it facilitates to isolate each medical formulation into a unique legal entity. This risk management strategy aligns with industry practices aimed at simplifying financing and partnerships, streamlining intellectual property and licensing processes. The choice of Texas as the jurisdiction for patent housing is driven by its business-friendly environment, including favorable judicial precedents, cost-effective litigation, and access to federal courts adept in handling complex cases.

Therefore, this calculated maneuver would place CBIH in a strong defensive posture in the event of legal challenges, and it is foreseen to lessen potential legal liabilities of the parent corporation. The decision to proceed with this collaboration followed medical legal standards to mitigate any potential medical conflicts arising from the studies, upholding ethical standards to maintain credibility and executing CBIH?s protocols effectively, which could lead to improved statistical significance. Overall, this partnership offers a platform for funding CBIH?s projects, safeguards both parties from risks related to intellectual property and litigation, and ensures the meticulous and ethical collection of data.

CBIH and Vita Biotech look forward to potentially bolster the credibility of their research among leading pharmaceutical companies, paving the way as pioneers in medical cannabis clinical research.